MacroGenics, Inc. (MGNX) Reaches $23.91 52-Week High; Endurant Capital Management LP Has Trimmed Oxford Immunotec Global Plc (OXFD) Position By $304,400

February 15, 2018 - By Ellis Scott

Endurant Capital Management Lp decreased Oxford Immunotec Global Plc (OXFD) stake by 2.53% reported in 2017Q3 SEC filing. Endurant Capital Management Lp sold 19,025 shares as Oxford Immunotec Global Plc (OXFD)’s stock rose 4.03%. The Endurant Capital Management Lp holds 731,509 shares with $12.29M value, down from 750,534 last quarter. Oxford Immunotec Global Plc now has $304.65 million valuation. The stock increased 3.62% or $0.41 during the last trading session, reaching $11.87. About 10,712 shares traded. Oxford Immunotec Global PLC (NASDAQ:OXFD) has risen 54.26% since February 15, 2017 and is uptrending. It has outperformed by 37.56% the S&P500.

The stock of MacroGenics, Inc. (NASDAQ:MGNX) hit a new 52-week high and has $25.58 target or 7.00% above today’s $23.91 share price. The 6 months bullish chart indicates low risk for the $880.43 million company. The 1-year high was reported on Feb, 15 by Barchart.com. If the $25.58 price target is reached, the company will be worth $61.63M more. The stock increased 0.25% or $0.06 during the last trading session, reaching $23.91. About 33,754 shares traded. MacroGenics, Inc. (NASDAQ:MGNX) has declined 9.76% since February 15, 2017 and is downtrending. It has underperformed by 26.46% the S&P500.

Endurant Capital Management Lp increased Davita Inc (NYSE:DVA) stake by 88,726 shares to 274,223 valued at $16.29M in 2017Q3. It also upped Nektar Therapeutics (NASDAQ:NKTR) stake by 66,500 shares and now owns 109,300 shares. Aetna Inc New (NYSE:AET) was raised too.

Investors sentiment decreased to 1.13 in 2017 Q3. Its down 0.14, from 1.27 in 2017Q2. It is negative, as 3 investors sold OXFD shares while 27 reduced holdings. 12 funds opened positions while 22 raised stakes. 22.51 million shares or 13.08% more from 19.91 million shares in 2017Q2 were reported. Neuberger Berman Group Inc Ltd Liability Corp holds 0% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 77,257 shares. Cortina Asset Management Ltd Com invested in 563,290 shares. 36,641 are owned by California State Teachers Retirement Sys. United Svcs Automobile Association has invested 0.01% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Tower Capital Ltd Limited Liability Company (Trc) has invested 0.01% in Oxford Immunotec Global PLC (NASDAQ:OXFD). D E Shaw Inc has invested 0% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Blackrock invested in 0% or 1.02M shares. Moreover, Tiverton Asset Mgmt Ltd Com has 0.17% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 175,000 shares. Moreover, Redmile Grp Inc Lc has 1.7% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 2.05M shares. Bnp Paribas Arbitrage holds 0% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 2,226 shares. Bank & Trust Of Montreal Can invested 0% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD). Granahan Ma holds 501,307 shares. Ardsley Advisory Prtn reported 0.03% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD). Manufacturers Life Insurance Commerce The accumulated 17,544 shares. National Bank Of New York Mellon holds 0% in Oxford Immunotec Global PLC (NASDAQ:OXFD) or 63,723 shares.

Among 4 analysts covering Oxford Immunotec (NASDAQ:OXFD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Oxford Immunotec had 10 analyst reports since July 19, 2017 according to SRatingsIntel. BTIG Research initiated the shares of OXFD in report on Thursday, September 28 with “Buy” rating. The firm has “Buy” rating by Cowen & Co given on Monday, January 22. As per Wednesday, July 19, the company rating was maintained by Cowen & Co. The stock has “Buy” rating by Cowen & Co on Tuesday, October 31. The rating was maintained by Cowen & Co on Wednesday, August 16 with “Buy”. The rating was maintained by Robert W. Baird on Thursday, October 19 with “Buy”. The rating was maintained by Cowen & Co on Wednesday, September 27 with “Buy”. Piper Jaffray maintained Oxford Immunotec Global PLC (NASDAQ:OXFD) rating on Monday, January 8. Piper Jaffray has “Buy” rating and $15.0 target. The stock of Oxford Immunotec Global PLC (NASDAQ:OXFD) earned “Buy” rating by Robert W. Baird on Tuesday, October 31.

Analysts await Oxford Immunotec Global PLC (NASDAQ:OXFD) to report earnings on February, 27. They expect $-0.36 earnings per share, down 63.64% or $0.14 from last year’s $-0.22 per share. After $-0.24 actual earnings per share reported by Oxford Immunotec Global PLC for the previous quarter, Wall Street now forecasts 50.00% negative EPS growth.

Since August 15, 2017, it had 0 insider purchases, and 2 sales for $970,393 activity. SANDBERG RICHARD A had sold 3,000 shares worth $47,460. Another trade for 55,000 shares valued at $922,933 was sold by Wrighton-Smith Peter. Edwardson Peter had sold 9,739 shares worth $157,171.

Since October 25, 2017, it had 0 insider buys, and 3 selling transactions for $367,500 activity. Shares for $200,000 were sold by Wigginton Jon Marc on Wednesday, October 25. Shares for $67,500 were sold by Risser Eric Blasius.

Analysts await MacroGenics, Inc. (NASDAQ:MGNX) to report earnings on February, 27. They expect $2.58 EPS, up 358.00% or $3.58 from last year’s $-1 per share. MGNX’s profit will be $95.00M for 2.32 P/E if the $2.58 EPS becomes a reality. After $-1.28 actual EPS reported by MacroGenics, Inc. for the previous quarter, Wall Street now forecasts -301.56% EPS growth.

Among 10 analysts covering MacroGenics (NASDAQ:MGNX), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. MacroGenics has $56 highest and $20 lowest target. $28.29’s average target is 18.32% above currents $23.91 stock price. MacroGenics had 22 analyst reports since August 6, 2015 according to SRatingsIntel. Stifel Nicolaus maintained the shares of MGNX in report on Monday, September 11 with “Buy” rating. The company was initiated on Thursday, February 25 by Morgan Stanley. The stock has “Buy” rating by Janney Capital on Thursday, February 18. The stock has “Buy” rating by BTIG Research on Friday, January 19. Stifel Nicolaus maintained the shares of MGNX in report on Thursday, August 6 with “Buy” rating. The rating was maintained by SunTrust with “Buy” on Tuesday, January 23. The company was maintained on Friday, September 1 by SunTrust. Leerink Swann maintained MacroGenics, Inc. (NASDAQ:MGNX) on Wednesday, October 25 with “Buy” rating. The rating was initiated by SunTrust with “Buy” on Tuesday, December 20. On Monday, August 7 the stock rating was maintained by Morgan Stanley with “Equal-Weight”.

Investors sentiment decreased to 1.58 in Q3 2017. Its down 0.15, from 1.73 in 2017Q2. It fall, as 7 investors sold MacroGenics, Inc. shares while 26 reduced holdings. 11 funds opened positions while 41 raised stakes. 27.72 million shares or 0.96% more from 27.45 million shares in 2017Q2 were reported. Evercore Wealth Ltd Liability Corp owns 0.01% invested in MacroGenics, Inc. (NASDAQ:MGNX) for 17,543 shares. Tocqueville Asset Limited Partnership, New York-based fund reported 100,000 shares. Pub Employees Retirement System Of Ohio reported 0% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX). Axa holds 0% or 14,200 shares in its portfolio. Invesco holds 0% or 16,168 shares in its portfolio. Credit Suisse Ag invested 0% in MacroGenics, Inc. (NASDAQ:MGNX). Moreover, Eventide Asset Limited Liability Company has 0.15% invested in MacroGenics, Inc. (NASDAQ:MGNX). Pinnacle Assoc Ltd has 843,175 shares. Tiger Mgmt Ltd has invested 0.8% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX). Legal And General Gru Plc reported 0% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX). Goldman Sachs Group holds 0% or 61,267 shares. 363,676 are held by Baker Bros Advsrs Limited Partnership. Swiss National Bank & Trust holds 55,200 shares. Oakworth Cap Inc stated it has 0% in MacroGenics, Inc. (NASDAQ:MGNX). Amer Grp Incorporated holds 22,305 shares or 0% of its portfolio.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>